This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Seocalcitol
Description: A number of preclinical studies have shown that Vitamin D, or more specifically its biologically active metabolite calcitriol, has anticancer activity in a number of different tumors including prostate, breast, pancreas, colon, skin and brain cancer. Calcitriol has many mechanisms of action in cancer including the ability to inhibit cell proliferation and angiogenesis, and induce differentiation and apoptosis.
CB1089 (Seocalcitol) is an analog of calcitriol that has been shown, in pre-clinical cancer studies, to be 50-200 times more potent than calcitriol with respect to regulation of cell growth and differentiation.
Deal Structure: In June 2005, Cougar Biotechnology licensed the worldwide, exclusive rights to seocalcitol from LEO Pharma A/S. Under the terms of the licensing agreement, LEO Pharma received an upfront payment and will receive milestone payments as seocalcitol progresses through clinical development as well as a royalty on sales.
In May 2009, Johnson & Johnson and Cougar Biotechnology announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Under the terms of the agreement, Johnson & Johnson will initiate a tender offer, through a new wholly-owned subsidiary, to purchase all outstanding shares of Cougar Biotechnology at $43 per share. The tender offer is conditioned on the tender of a majority of the outstanding shares of Cougar Biotechnology's common stock. The $970 million estimated net value of the transaction is based on Cougar Biotechnology's 20.8 million shares outstanding, net of estimated cash on hand at...See full deal structure in Biomedtracker
Partners: LEO Pharma A/S
Additional information available to subscribers only: